| Literature DB >> 33919336 |
Joanna Sobska1,2,3,4,5, Magdalena Waszkielewicz6, Anna Podleśny-Drabiniok2,3,4,5, Joanna Olesiak-Banska1, Wojciech Krężel2,3,4,5, Katarzyna Matczyszyn1.
Abstract
Gold nanoparticles hold a great promise for both clinical and preclinical applications. The major factors impeding such applications are toxicity of new nanomaterials including e.g., pro-apoptotic activities or inflammatory effects, but also their potential to accumulate in the body or inadequate absorption, distribution, metabolism and excretion (ADME) profiles. Since such adverse effects depend on the size, form and coating of nanomaterials, the search for new, less toxic nanomaterials with low tendency to accumulate is highly active domain of research. Here, we describe optical and biological properties of Au18 gold nanoclusters (NCs), small gold nanoparticles composed of 18 atoms of gold and stabilized with glutathione ligands. These nanoclusters may be suitable for in vivo applications owing to their low toxicity and biodistribution profile. Specifically, using lactate dehydrogenase (LDH) test in P19 cell line we found that Au18 NCs display low toxicity in vitro. Importantly, using primary microglial cells we showed that at low concentrations Au18 NCs display anti-inflammatory signaling on evidence of reduced interleukin 1-β (IL1-β) levels and unchanged levels of tumor necrosis factor (TNF-α) or Ym1/2. Such effect was dose dependent as higher concentrations of Au18 NCs induced expression of pro-inflammatory cytokines and suppression of anti-inflammatory cytokine Ym1/2, pointing, thus, to global inflammatory activity. Finally, we also showed that within 3 days Au18 NCs can be completely eliminated from the liver reported as the major target organ for accumulation of gold nanoparticles. These data point to a potential of gold nanoparticles for further biomedical studies.Entities:
Keywords: biodistribution; cytotoxicity; immunological response; nanoparticles
Year: 2021 PMID: 33919336 PMCID: PMC8143360 DOI: 10.3390/nano11051066
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Combinations of forward and reverse primers used in real-time PCR expression analysis.
| Gene | ||
|---|---|---|
| 36B4 | Forward sequence (5´→3´) | ACCCTGAAGTGCTCGACATC |
| TNF-α | Forward sequence (5´→3´) | CTTCTGTCTACTGAACTTCGGG |
| Il1-β | Forward sequence (5´→3´) | ACGGACCCCAAAAGATGAAG |
| Ym1/2 | Forward sequence (5´→3´) | CAGGGTAATGAGTGGGTTGG |
Figure 1(A) Absorption spectrum of an aqueous solution of Au18. (B) TEM image of Au18 nanoclusters (NCs) solution. (C) Excitation (black) and emission (red) spectra of Au18 NCs. The sample was excited at 540 nm and the maximum of the emission was at 640 nm.
Figure 2Cytotoxicity of Au18 NCs on P19 cells in lactate dehydrogenase (LDH) test. P19cells were incubated with culture medium containing NCs at concentrations between 0.006 ppm to 6.0 ppm and were compared to vehicle (H2O) treated cells (negative control) at 3, 24 and 48 h. Non-treated cells were also reported as no effect of vehicle was observed. Each experimental group consisted of n = 3 independent samples and error bars represent standard error of means. *** p < 0.001 as compare to vehicle treated cells.
Figure 3Inflammatory responses of mouse primary microglia cells in response to Au18 NCs. Primary microglia cells were treated with Au18 NCs (0.006 ppm, 0.6 ppm, 6.0 ppm) or lypopolysaccharyde (LPS) (125 ng/mL) and cultured during 3 h. The expression of interleukin 1-β (IL-1β), tumor necrosis factor (TNF-α) and Ym1/2 was examined using RT-qPCR (n = 3/group, * p < 0.05; *** p < 0.001 as compare to untreated cells).
Figure 4Biodistribution of Au18 NCs in mice. Au concentration measured with inductively coupled plasma optical emission spectrometer (ICP-OES) in non-treated control mice (CTR) and at 3, 24 and 72 h post intraperitoneal injections. Values are represented as mean ± SEM (n = 3/time/organ, *** p < 0.001 as compared to negative control, CTR).